NEW YORK, NY, April 23, 2015 /CNW Telbec/ - Crystal Research
Associates, LLC announced today that it has issued an Executive
Informational Overview® (EIO) on Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ). The full 52-page report is
available on Crystal Research Associates' website at
www.crystalra.com as well as on Aeterna Zentaris' website at
www.aezsinc.com.
Aeterna Zentaris ("Aeterna" or "the Company") is transitioning
into a specialty biopharmaceutical company in oncology,
endocrinology, and women's health. With a focus on establishing
revenues and profitability while optimizing resources to reduce its
burn rate, the Company co-promotes a non-patch estrogen replacement
therapy, EstroGel®, in specific U.S. markets with partner, Ascend
Therapeutics ("Ascend"). As well, Aeterna holds a pipeline of
candidates in varying stages of development and is working to
acquire, in-license, or co-promote other commercial compounds.
The Company's most advanced wholly owned clinical candidate,
zoptarelin doxorubicin (doxorubicin peptide conjugate targeting
LHRH receptor–expressing tumors), is in a Phase 3 trial in
advanced, recurrent, or metastatic endometrial cancer—a disease for
which patients typically have a poor prognosis and there is no
approved systemic therapy. Aeterna's pipeline further includes
Macrilen™, a drug for the evaluation of Adult Growth Hormone
Deficiency (AGHD), for which the Company intends to initiate a
confirmatory Phase 3 program, as well as other compounds in
oncology, as the Company works to pursue strategic initiatives
consistent with becoming a commercially operating specialty
biopharmaceutical company.
Be the first to hear about Crystal Research's new report
releases and upcoming media coverage. Follow us at
http://www.crystalra.com/blog for more coverage.
About Crystal Research Associates, LLC
For the past decade, Crystal Research Associates, LLC
(www.crystalra.com) has successfully articulated the exceptional
stories of small- and mid-cap companies to the Wall Street investor
community. Our methods are well-established and diverse, from
compiling and disseminating objective, factual information for both
institutional and retail investor audiences to capitalizing on our
expansive line of targeted distribution channels, which include
industry-leading financial data and information providers. Our
distribution efforts are accompanied by the use of prominent social
media channels and by strategic and targeted appearances on
national news programs and print media.
Crystal Research Associates is led by Wall Street veterans,
Jeffrey Kraws and Karen Goldfarb. Together, Kraws and Goldfarb
have built a unique business model, capitalizing on decades of
experience as an award-winning sell-side analyst team to produce
institutional-quality industry and market research in a manner that
is easily understood by investors and consumers. Our firm's
approach has been proven successful over the years as our products
are published and available on Bloomberg, Thomson Reuters/First
Call, Capital IQ, FactSet, Yahoo! Finance, and scores of other
popular forums.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and
operating results, potential applications of the Company's
technology, opportunities for the Company, and any other statements
about the future expectations, beliefs, goals, plans, or prospects
expressed constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words "will," "believes," "plans,"
"anticipates," "expects," "estimates," and similar expressions)
should also be considered forward-looking statements. There are a
number of important factors that could cause actual results or
events to differ materially from those indicated by such
forward-looking statements, including limited operating history,
need for future capital, and economic conditions generally.
Additional information on potential factors that could affect
results and other risks and uncertainties are detailed from time to
time in the Company's periodic news and reports. Crystal Research
Associates' compensation is a cash amount of thirty-nine thousand U.S. dollars for its
services in creating this report and other communications
products.
These statements, and other forward-looking statements, are not
guarantees of future performance and involve risks and
uncertainties. Crystal Research Associates assumes no obligation to
update any of the forward-looking statements in this release.
SOURCE Aeterna Zentaris Inc.